Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In
  • Become a Member
  • MB Vision
  • Members
    • Become a Member
      • Types & Rates
    • Benefits
      • Savings and Rewards
    • Member News
    • Member Events
    • Career Center
    • Directory
    • Pay Company Dues
    • FAQs
  • Events
    • Upcoming
    • Types of Events
    • Sponsorship Opportunities
    • The State of Possible Conference
    • Align Summit
    • Member Events
  • Innovation
    • About
    • MassBioDrive
      • Application
      • Alumni
      • Partners
      • Get Involved
      • FAQs
    • CEO & Founder Link
    • Align Summit
    • Partnering
    • Sponsorship Opportunities
  • Savings
    • MassBioEdge
  • Conference Center
    • About MassBioHub
    • Packages & Special Offers
    • Venue Specifications
    • Reserve Today
  • Policy & Advocacy
    • Policy & Advocacy Efforts
    • Diversity, Equity, and Inclusion
      • DEI Report
      • Resource Center
      • Open Letter 2.0
      • Bioversity
    • Economic Development
      • BioReady® Communities
    • Workforce Development
      • Bioversity
    • Vision 2030
    • This is the place.
    • Industry Reports
      • Federal Actions Impact Report
      • Industry Snapshot
      • Biopharma Funding Report
      • DEI Report
      • MA Life Sciences Workforce
  • About
    • About MassBio
    • News & Thought Leadership
    • MB Vision
    • The Studio at Kendall Square
    • Sponsorship Opportunities
    • Staff
    • Board
    • Contact Us
  • Sign In
  • Become a Member
  • MB Vision
Open search form

Member Directory

Click to Open Main Menu

Alloplex Biotherapeutics, Inc

Life Sciences | Drug Development
Woburn, MA 8572721214

Overview

Alloplex Biotherapeutics is an angel funded private biotechnology company dedicated to the goal of developing an off-the-shelf anti-tumor vaccine. Our approach involves genetically engineering an allogeneic tumor cell line to express an optimal set of proprietary immunomodulatory gene cassettes intended to enhance discrete immunologic functions. We are employing an all human in vitro assay to efficiently select and optimize vaccine candidates for our lead melanoma indication. By avoiding artifact prone preclinical animal models, we expect to improve the likelihood that the in vitro results will translate to the clinical setting. This approach is the basis of a platform technology with applicability across multiple tumor types and is also ideally suited for combination with the checkpoint inhibitor class of biologics that have recently become the standard-of-care in melanoma. We anticipate initiating a small Phase I trial by end of 2019 with the goal of demonstrating enhanced anti-tumor reactivity in peripheral blood cells in the context of a benign safety profile. Additional larger registration trials will be focused on achieving meaningful improvements in the standard efficacy endpoints of progression-free survival and overall survival.

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • News & Thought Leadership
  • Pay Company Dues
  • Join Today
  • Contact
  • Privacy Policy
  • © 2025 All Rights Reserved